Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Reviva Pharmaceuticals Holdings, retaining the price target of $2.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Reviva Pharmaceuticals Holdings’ promising future. The company is preparing for a critical pre-NDA meeting with the FDA, expected before the end of 2025, which will provide clarity on the regulatory path for their schizophrenia treatment, brilaroxazine. A positive outcome from this meeting could pave the way for a New Drug Application submission by the second quarter of 2026, supported by encouraging Phase 2 and Phase 3 trial results, as well as additional study data.
Moreover, Reviva’s financial position appears stable with recent financing activities, including a $9 million equity raise and an additional $6.4 million from warrant exercises, extending their cash runway into 2026. The company’s recent presentations at major conferences, showcasing positive long-term efficacy and safety data for brilaroxazine, further reinforce the potential for successful market entry. These elements collectively underpin McCarthy’s optimistic outlook and Buy recommendation for Reviva’s stock.
McCarthy covers the Healthcare sector, focusing on stocks such as SCYNEXIS, Neuphoria Therapeutics, and OS Therapies Incorporated. According to TipRanks, McCarthy has an average return of -19.0% and a 29.78% success rate on recommended stocks.
In another report released on November 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.